The Effect of Subcutaneous Teriparatide Treatment on Mobility, Back Pain, and Patient Satisfaction in Patients with Vertebral Osteoporotic Fractures: A Cross-Sectional Study with 36-Month Follow-up

Aim:Although the effectiveness of teriparatide on bone mineral density (BMD), fracture risk, and back pain in severe osteoporosis is known, no comprehensive study has been conducted in the Turkish population regarding its impact on mobility and patient satisfaction. This study aimed to evaluate the effectiveness of teriparatide treatment on mobility, back pain, and patient satisfaction in patients with osteoporotic vertebral fractures, as well as its side effects in midterm follow-up.Methods:The study was designed as a retrospective, cross-sectional study. Between February 2018 and April 2023, 50 consecutive patients (mean age 69.9±9.0 years; range, 53 to 94 years) who were diagnosed with vertebral fractures due to severe osteoporosis and had received 20 μg/day subcutaneous teriparatide (median, 18 months) were included in the study. The patients were evaluated using BMD measurements, blood tests, radiological imaging, a visual pain score (VAS-pain), mobility assessments [Functional Ambulation Classification (FAC)], and patient satisfaction levels at baseline, 6th, and 18th months.Results:At 6 and 18 months, a significant decrease in VAS-pain and a significant increase in BMD and FAC were observed (p